untitled design

Coronavirus: Pfizer will vaccinate entire city as part of research

The effectiveness of the vaccine against it coronavirus wants to explore the Pfizer Inc, announcing today that, to this end, it will vaccinate the entire population over the age of 12 in a city in southern Brazil.

The study will be conducted in the city Toledo, with population 143,000 inhabitants, in the western part of the state of Paran., in collaboration with the National Vaccination Program of Brazil, the local authorities, a city hospital and a university in the area, according to the APE BPE.

Pfizer said the goal is to study the transmission of the new coronavirus in a “real-life scenario”. after the population will have been vaccinated.

“The initiative is first one and the unique of its kind, which will be undertaken in collaboration with the pharmaceutical company in a developing country “, stressed Pfizer.

“Here, we believe in science and mourn the nearly 600,000 deaths from Covid-19 in Brazil,” said the mayor of Toledo. Beto Luniti, in a press conference he gave in connection with the Pfizer study.

For his part, o Regis Wallart, a researcher at Moinhos de Vento Hospital in Toledo, reiterated that the aim of the study was to validate in vaccine the effectiveness and safety of the vaccine, as recorded in clinical trials.

According to him, the study will also be an opportunity to have long-term observation, in depth up to one year, the participants and answer questions such as duration vaccination coverage against covid-19 and youngsters variants of the virus.

What a similar survey in a smaller town showed for CoronaVac

According to Reuters, a similar investigation was conducted by Butantan Institute, one of the leading biomedical research centers in Brazil, the smallest city Seranas, in the state of Sao Paulo, in order to study the vaccine CoronaVac of Chinese Sinovac Biotech Ltd.

In May, the Butantan Institute said mass vaccination had reduced Covid-19 deaths by 95% in the city with a population of 45,644 inhabitants.

The institute is considering expanding its research to one third dose.

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular